Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENZENO: ZB716 Monotherapy and in Combination With Palbociclib in ER+, HER2- Breast Cancer
NCT04669587Phase 2Unknown
- Sponsor
- EnhancedBio
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of zb716 in breast cancer, sponsored by EnhancedBio. Status: unknown.
02
Drugs
zb716
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04669587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669587.